Exploiting human genetic variation in drug discovery and development

Drug Discovery Today

Volumn 6, Issue 4, 2001, Pages 198-205

  Jazwinska, Elizabeth C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; DRUG LEGISLATION; DRUG RESPONSE; DRUG TARGETING; GENETIC ANALYSIS; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MEDICAL GENETICS; PHARMACOGENETICS; PRESCRIPTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0035254224     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01642-1     Document Type: Review

References (41)

1. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis
2. The human genome project. Prospects and implications for clinical medicine
3. The evolving genome project: current and future impact
4. Human genome. Finally, the book of life and instructions for navigating it
5. Working draft' of human genome completed
6. More than 1,000 putative new human signalling proteins revealed by EST data mining
7. Computational approaches for gene identification
8. Analysis of EST-driven gene annotation in human genomic sequence
9. The essence of SNPs
10. The use of single-nucleotide polymorphism maps in pharmacogenomics
11. The Human Genome Project - an overview
12. As consortium plans free SNP map of human genome
13. Linkage disequilibrium mapping of complex disease: fantasy or reality?
14. How many diseases does it take to map a gene with SNPs?
15. Y chromosome sequence variation and the history of human populations
16. Population genetics - making sense out of sequence
17. History of drugs for thrombotic disease. Discovery, development, and directions for the future
18. Drug discovery and development in the molecular era
19. Alternative strategies in drug development: clinical pharmacological aspects
20. Populations and genetic polymorphisms
21. Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), ( opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF))
22. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
23. Pharmacogenetics
24. Can pharmacogenomics make a difference in drug development?
25. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications
26. Pharmacogenetics and the future of drug development and delivery
27. Pharmacogenetics and the practice of medicine
28. Single-nucleotide polymorphisms, haplotypes, and their relevance to pharmacogenetics
29. A SNPshot: pharmacogenetics and the future of drug therapy
30. Pharmacogenomics: translating functional genomics into rational therapeutics
31. Molecular characterization of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694
32. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm
33. Ethical and legal issues in the procurement, storage and use of DNA
34. Antiepileptic drug pharmacogenetics
35. Pharmacogenetics and psychopharmacotherapy
36. Prospects for whole-genome linkage disequilibrium mapping of common disease genes
37. Genetics of complex disease: approaches, problems, and solutions
38. The use of association data to identify family members at high risk for marker-linked diseases
39. HLA haplotype sharing in rheumatoid arthritis sibships: risk estimates subdivided by proband genotype
40. Carrier detection of Batten disease (juvenile neuronal ceroid-lipofuscinosis)
41. Hemochromatosis: a genetic defect in iron metabolism